Trial to Assess Efficacy and Safety of Lacosamide in Subjects With Osteoarthritis of the Knee
July 28, 2017 updated by: UCB Pharma
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Osteoarthritis of the Knee
The purpose of this trial is to evaluate the effectiveness, safety and tolerability of lacosamide (LCM) 400mg/day in treating the signs and symptoms of osteoarthritis of the knee.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
LCM is an investigational drug that is being studied as a treatment in male and female patients who are diagnosed with osteoarthritis of the knee and require therapeutic doses of NSAIDs, COX-2 NSAIDs and/or paracetamol. This trial will be conducted exclusively in Europe.
The study has an adaptive 3-stage group sequential design.
The trial will last a total of 17 weeks. There will be a 2 week period to wean off current medication, followed by a 4 week period where the patient will receive placebo (inactive drug) or gradually increasing doses of LCM up to the target dose of 400mg/day. The target dose or placebo will be maintained for 8 weeks followed by a 1 week reduction period then a 2 week safety follow up period.
The last subject is expected to be enrolled in December 2007.
The study was terminated based on the outcome of the planned first interim analysis, which was performed as defined in the protocol in a subset of patients. It was decided not to continue the trial. No safety concerns were identified.
Study Type
Interventional
Enrollment (Actual)
194
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kladno, Czechia
-
Prague, Czechia
-
-
-
-
-
Bad Hersfeld, Germany
-
Berlin, Germany
-
Hamburg, Germany
-
Leipzig, Germany
-
München, Germany
-
-
-
-
-
Debrecen, Hungary
-
Esztegom, Hungary
-
Gyor, Hungary
-
Gyula, Hungary
-
Verseghy, Hungary
-
Veszprem, Hungary
-
-
-
-
-
Bialystok, Poland
-
Krakow, Poland
-
Torun, Poland
-
Warszawa, Poland
-
-
-
-
-
Braila, Romania
-
Lasi, Romania
-
Targoviste, Romania
-
Timisoara, Romania
-
-
-
-
-
Stockholm, Sweden
-
-
-
-
-
Morriston, United Kingdom
-
Newcastle, United Kingdom
-
Oxford, United Kingdom
-
Stanmore, United Kingdom
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject has symptomatic osteoarthritis of the knee diagnosed using clinical and radiographic evidence as well as ACR criteria with symptom duration of at least 6 months.
- Subject requires therapeutic dose of an NSAID, COX-2 NSAID, and/or paracetamol/acetaminophen for osteoarthritis pain of the index knee and has taken that medication at least 5 days per week for the last 4 weeks prior to the screening visit (Visit 1).
Exclusion Criteria:
- Subject is not able to withdraw NSAIDs, COX-2 NSAIDs and/or paracetamol
- Subject is taking analgesic other than NSAIDs COX-2 NSAIDs and/or paracetamol
- Subject is planning to begin or stop treatment with glucosamine and/or chondroitin during the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
|
|
EXPERIMENTAL: Lacosamide
lacosamide (LCM)
|
50 or 100mg tablet, 400mg daily, for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of the Western Ontario and McMaster Universities (WOMAC) Pain Subscale Score (Visual Analogue Scale Version) From Baseline to the End of the 8 Week Maintenance Period
Time Frame: Baseline, end of 8 week Maintenance Period
|
The Visual Analogue Scale (VAS) version of the WOMAC pain subscale ranges from 0 to 100, high values describe high grade of pain.
|
Baseline, end of 8 week Maintenance Period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline to End of 8 Week Maintenance Period in WOMAC Physical Function Subscale Score.
Time Frame: Baseline, end of 8 week Maintenance Period
|
The WOMAC physical function subscale score (Visual Analogue Scale version) ranges from 0 to 100, high values describe high grade of difficulty in performing daily activities.
|
Baseline, end of 8 week Maintenance Period
|
|
Change From Baseline to End of 8 Week Maintenance Period in WOMAC Stiffness Subscale Score.
Time Frame: Baseline, end of 8 week Maintenance Period
|
The WOMAC stiffness subscale score (Visual Analogue Scale version) ranges from 0 to 100, high values describe high grade of stiffness.
|
Baseline, end of 8 week Maintenance Period
|
|
Change From Baseline to End of 8 Week Maintenance Period in Total WOMAC Score.
Time Frame: Baseline, end of 8 week Maintenance Period
|
The WOMAC total score is the sum of the normalized subscale scores for pain, stiffness, and physical function and ranges from 0 to 300, high values describe high grade of impact.
|
Baseline, end of 8 week Maintenance Period
|
|
Patient's Global Impression of Change From Baseline at the End of 8 Week Maintenance Period.
Time Frame: at the end of 8 week Maintenance Period
|
Patient's global impression of change from baseline is a score that ranges from 'very much worse' to 'very much improved'.
|
at the end of 8 week Maintenance Period
|
|
Response at the End of 8 Week Maintenance Period Versus Baseline Based on the (Slightly Modified)Criteria of the Osteoarthritis Research Society International (OARSI) and the Outcome Measures in Rheumatology Initiative (OMERACT).
Time Frame: Baseline, end of 8 week Maintenance Period
|
Improvement = reduction of >= 20% and >= 10 mm in both WOMAC pain and physical function subscale.
Those who met the criteria in either of the subscales had improved if response to Patient's Global Impression of change from baseline was at least 'mildly improved'.
High improvement = reduction of >= 50% and >= 20 mm in either of the subscales.
Response = either high improvement or improvement.
|
Baseline, end of 8 week Maintenance Period
|
|
Amount of Rescue Medication Use During 8 Week Maintenance Period.
Time Frame: during 8 week Maintenance Period
|
Use of rescue medication is expressed in number of tablets equivalent to 500 mg Paracetamol per day.
|
during 8 week Maintenance Period
|
|
Change From Baseline to End of 8 Week Maintenance Period in Perception of Pain Interference With Subject's Sleep.
Time Frame: Baseline, end of 8 week Maintenance Period
|
Pain interference with sleep refers to patient's last evening prior to the visit and was assessed using a 100mm visual analog scale (VAS).
The VAS ranges from 0 (did not interfere) to 100 (completely interfered).
|
Baseline, end of 8 week Maintenance Period
|
|
Change From Baseline to End of 8 Week Maintenance Period in Profile of Mood States (Total Mood Disturbance Score).
Time Frame: Baseline, end of 8 week Maintenance Period
|
Total Mood Disturbance score sums up over the domain scores regarding Tension-anxiety, Depression-ejection, Anger-hostility, Vigor-activity (was subtracted), Fatigue-inertia, Confusion-bewilderment. Domain scores were derived as sum of the respective items and range from 0 to 20.
With exception of Vigor-activity high values describe bad mood.
|
Baseline, end of 8 week Maintenance Period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2007
Primary Completion (ACTUAL)
November 1, 2007
Study Completion (ACTUAL)
January 1, 2008
Study Registration Dates
First Submitted
June 12, 2007
First Submitted That Met QC Criteria
June 12, 2007
First Posted (ESTIMATE)
June 13, 2007
Study Record Updates
Last Update Posted (ACTUAL)
August 28, 2017
Last Update Submitted That Met QC Criteria
July 28, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP0905
- 2006-005048-97 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.